AU2005215262B2 - New combinations of an anti emetic agent and an enkephalinase inhibitor - Google Patents

New combinations of an anti emetic agent and an enkephalinase inhibitor Download PDF

Info

Publication number
AU2005215262B2
AU2005215262B2 AU2005215262A AU2005215262A AU2005215262B2 AU 2005215262 B2 AU2005215262 B2 AU 2005215262B2 AU 2005215262 A AU2005215262 A AU 2005215262A AU 2005215262 A AU2005215262 A AU 2005215262A AU 2005215262 B2 AU2005215262 B2 AU 2005215262B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
treatment
diarrhoea
composition according
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005215262A
Other languages
English (en)
Other versions
AU2005215262A1 (en
Inventor
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Bioprojet SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005215262(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet SC filed Critical Bioprojet SC
Publication of AU2005215262A1 publication Critical patent/AU2005215262A1/en
Application granted granted Critical
Publication of AU2005215262B2 publication Critical patent/AU2005215262B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2005215262A 2004-02-12 2005-02-14 New combinations of an anti emetic agent and an enkephalinase inhibitor Ceased AU2005215262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290384.9 2004-02-12
EP04290384A EP1563848A1 (en) 2004-02-12 2004-02-12 New combinations of an anti-emetic agent and an enkephalinase inhibitor
PCT/IB2005/000351 WO2005079850A1 (en) 2004-02-12 2005-02-14 New combinations of an anti emetic agent and an enkephalinase inhibitor

Publications (2)

Publication Number Publication Date
AU2005215262A1 AU2005215262A1 (en) 2005-09-01
AU2005215262B2 true AU2005215262B2 (en) 2011-03-03

Family

ID=34684783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005215262A Ceased AU2005215262B2 (en) 2004-02-12 2005-02-14 New combinations of an anti emetic agent and an enkephalinase inhibitor

Country Status (28)

Country Link
US (1) US8222294B2 (enExample)
EP (2) EP1563848A1 (enExample)
JP (1) JP4987487B2 (enExample)
KR (1) KR101152308B1 (enExample)
CN (1) CN1917903B (enExample)
AT (1) ATE468138T1 (enExample)
AU (1) AU2005215262B2 (enExample)
BR (1) BRPI0506631B8 (enExample)
CA (1) CA2553827C (enExample)
CY (1) CY1110202T1 (enExample)
DE (1) DE602005021317D1 (enExample)
DK (1) DK1718337T3 (enExample)
EA (1) EA010625B1 (enExample)
EC (1) ECSP066758A (enExample)
ES (1) ES2344909T3 (enExample)
HR (1) HRP20100363T1 (enExample)
MA (1) MA28354A1 (enExample)
ME (1) ME01175B (enExample)
NO (1) NO337320B1 (enExample)
NZ (1) NZ548635A (enExample)
PL (1) PL1718337T3 (enExample)
PT (1) PT1718337E (enExample)
RS (1) RS51329B (enExample)
SI (1) SI1718337T1 (enExample)
TN (1) TNSN06246A1 (enExample)
UA (1) UA88156C2 (enExample)
WO (1) WO2005079850A1 (enExample)
ZA (1) ZA200605872B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
EP2462922A1 (en) * 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
EP2866789B1 (en) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) * 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
PT2866802T (pt) * 2012-06-28 2016-09-05 Johnson & Johnson Consumer Inc Composições líquidas racecadotril
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Aliment Pharm Ther, 1997, 11(1): 185-191 *
Ann Emerg Med, 2002, 39(4): 397-403 *
Bul Canc, 2001, 88(2): 163-173 *
Gastroentero, 1999, 116(4)[2]: A859 *
Int J Antimicro Ag, 2000, 14(1): 81-87 *
Lancet, 1997, 349(9061): 1293 *

Also Published As

Publication number Publication date
ATE468138T1 (de) 2010-06-15
CY1110202T1 (el) 2015-01-14
DK1718337T3 (da) 2010-07-26
JP4987487B2 (ja) 2012-07-25
CA2553827C (en) 2012-08-07
SI1718337T1 (sl) 2010-08-31
MA28354A1 (fr) 2006-12-01
US8222294B2 (en) 2012-07-17
ECSP066758A (es) 2006-11-24
KR20060132691A (ko) 2006-12-21
BRPI0506631B8 (pt) 2021-05-25
KR101152308B1 (ko) 2012-06-11
CA2553827A1 (en) 2005-09-01
NO20063973L (no) 2006-09-05
EP1718337B1 (en) 2010-05-19
US20070275993A1 (en) 2007-11-29
AU2005215262A1 (en) 2005-09-01
ZA200605872B (en) 2008-01-08
BRPI0506631A (pt) 2007-05-08
EP1718337A1 (en) 2006-11-08
JP2007522202A (ja) 2007-08-09
NO337320B1 (no) 2016-03-07
EA010625B1 (ru) 2008-10-30
PT1718337E (pt) 2010-06-16
DE602005021317D1 (de) 2010-07-01
NZ548635A (en) 2009-10-30
CN1917903A (zh) 2007-02-21
CN1917903B (zh) 2010-07-21
WO2005079850A1 (en) 2005-09-01
ES2344909T3 (es) 2010-09-09
BRPI0506631B1 (pt) 2018-12-04
ME01175B (me) 2013-03-20
EP1563848A1 (en) 2005-08-17
EA200601466A1 (ru) 2006-12-29
RS51329B (sr) 2011-02-28
UA88156C2 (ru) 2009-09-25
TNSN06246A1 (fr) 2007-12-03
PL1718337T3 (pl) 2010-09-30
HRP20100363T1 (hr) 2010-07-31

Similar Documents

Publication Publication Date Title
JP4855573B2 (ja) 抗ウイルス製剤の使用
CA1243605A (en) Antidiarrheal compositions and use thereof
EP0914124B1 (fr) COMPOSITION PHARMACEUTIQUE ANTITHROMBOTIQUE ET ANTIATHEROGENE COMPRENANT UN DERIVE DE THIENOPYRIDINE ET UN INHIBITEUR DE LA HMG-CoA-REDUCTASE
US20100273807A1 (en) Use of PDE III Inhibitors for the Treatment of Asymptomatic (Occult) Heart Failure
RU2284819C2 (ru) Стабильная пероральная твердая композиция лекарственного препарата
JP4632204B2 (ja) 下痢型過敏性腸症候群治療剤
CA2553827C (en) New combinations of an anti emetic agent and an enkephalinase inhibitor
US20080021083A1 (en) 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
CN108992456A (zh) 含有香叶木苷硫酸酯衍生物的药物组合物及其应用
EP1604660B1 (en) Medicinal composition for treating infection with drug-resistant staphylococcus aureus
CN102724977B (zh) 富里酸与氟康唑或两性霉素b组合用于真菌感染的治疗
JPH0152366B2 (enExample)
JP2003518502A (ja) 雄性の生殖毒性抑制に有効なペクチンを含む薬剤組成物
US7842702B2 (en) Treatment for irritable bowel syndrome
KR100593795B1 (ko) 안정성이 개선된 라미프릴을 포함하는 경구투여용 제제
JPS625923A (ja) アレルギ−性疾患治療剤
CZ367598A3 (cs) Použití substituovaného azaspiranu
MXPA00004122A (en) Metal/thiol biocides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired